Recent Updates
Recently added Catalysts

Transgastric endoscopic peritoneoscopy.

Phase 1

Pancreatic Cancer | Unknown | Oncology |Stryker Corporation|Last Updated: May 7, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00427752Abdominal Exploration Without IncisionsEARLY_PHASE1 COMPLETED 20 — — Oct 1, 2006Jan 1, 2012May 7, 20121 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
1) That transgastric endoscopic peritoneoscopy is feasible.
4/12
Secondary Endpoints
That bacterial abdominal contamination is not clinically significant.
04/11
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingSINGLE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
WhippleEXPERIMENTALPatients with pancreatic cancer who will proceed to a Whipple procedure.
Interventions
NameTypeDescription
Transgastric endoscopic peritoneoscopy.PROCEDUREExploration of the abdominal area
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Pancreatic Cancer undergoing staging laparoscopy * Staging or diagnostic laparoscopy in anyone needing enteral access Exclusion Criteria: * Lack of consent * Intra-abdominal adhesions precluding diagnostic laparoscopy

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Pancreatic Cancer 186 trials
CompanyTickerTrialsLead PhaseDrugs
Revolution Medicines, Inc.RVMD9PHASE3RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan
Arcus Biosciences, Inc.RCUS3PHASE3Quemliclustat, Nab-paclitaxel, Gemcitabine, Zimberelimab, Etrumadenant
AstraZeneca PLCAZN9PHASE2AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan
AngioDynamics, Inc.ANGO2PHASE3Modified FOLFIRINOX Regimen
Pfizer Inc.PFE9PHASE2tisotumab vedotin, pembrolizumab, carboplatin, cisplatin, ponsegromab
AbbVie, Inc.ABBV4PHASE2TTX-030, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine, Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina
Bristol-Myers Squibb CompanyBMY4PHASE2Navlimetostat, Gemcitabine, Nab-paclitaxel, BMS-986340, BMS-936558-01
Immuneering Corp. Class AIMRX2PHASE3Atebimetinib, GnP, mGnP, IMM-1-104 Monotherapy
RenovoRx, Inc.RNXT1PHASE3Gemcitabine, nab-paclitaxel
BioNTech SE Sponsored ADRBNTX2PHASE2Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX, Autogene cevumeran
Agenus Inc.AGEN5PHASE2Botensilimab, Gemcitabine, Nab-paclitaxel, AGEN1423, Balstilimab
Eli Lilly and CompanyLLY7PHASE1LY4101174, LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine
Merck & Co., Inc.MRK2PHASE2Belzutifan, Sacituzumab tirumotecan, Fluorouracil, Leucovorin or levoleucovorin, Cisplatin
Veracyte, Inc.VCYT1PHASE3Tislelizumab
ArriVent BioPharma, Inc.AVBP3PHASE2JAB-21822, MRG007, JAB-3312
Exelixis, Inc.EXEL1PHASE2Zanzalintinib, Everolimus
HUTCHMED (China) Limited Sponsored ADRHCM1PHASE2Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
ImmunityBio IncIBRX2PHASE2N-803, Aldoxorubicin, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine
Candel Therapeutics, Inc.CADL1PHASE2Aglatimagene besadenovec
Incyte CorporationINCY3PHASE2Ruxolitinib, Capecitabine, Regorafenib, Pemigatinib, Retifanlimab
Unlock Competitive Intelligence